NCNA
$1.86
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The co...
Recent News
European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading
European equities traded in the US as American depositary receipts edged lower late Wednesday mornin
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
European equities traded in the US as American depositary receipts late Tuesday morning, rising 1.12
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
European equities traded in the US as American depositary receipts were tracking slightly lower late
European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading; Down 5% for Week
European equities traded in the US as American depositary receipts were down sharply late Friday mor
European Equities Traded in the US as American Depositary Receipts Little Changed in Tuesday Trading
European equities traded in the US as American depositary receipts were little changed late Tuesday